AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Telix Pharmaceuticals under investigation for potential securities fraud.
ByAinvest
Saturday, Aug 9, 2025 11:57 am ET1min read
Pomerantz LLP is investigating claims against Telix Pharmaceuticals Limited regarding potential securities fraud and unlawful business practices. The investigation follows Telix's disclosure of a subpoena from the U.S. Securities and Exchange Commission regarding the company's prostate cancer therapeutic candidates. As a result, Telix's American Depositary Receipt price fell by 10.44%. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980 to discuss potential involvement in the class action.
Pomerantz LLP has initiated an investigation into potential securities fraud and unlawful business practices involving Telix Pharmaceuticals Limited (TLX). The investigation follows the company's disclosure of a subpoena from the U.S. Securities and Exchange Commission (SEC) on July 22, 2025, seeking documents and information related to the development of Telix's prostate cancer therapeutic candidates [2].On July 23, 2025, Telix's American Depositary Receipt (ADR) price fell by 10.44%, closing at $14.58 per ADR [2]. The investigation by Pomerantz LLP aims to determine whether Telix and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices [3].
Investors affected by this situation are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, to discuss potential involvement in the class action [3].
References:
[1] https://www.morningstar.com/news/business-wire/20250808663025/securities-fraud-investigation-into-marex-group-plc-mrx-announced-investors-who-lost-money-urged-to-contact-glancy-prongay-murray-llp-a-leading-securities-fraud-law-firm
[2] https://www.globenewswire.com/news-release/2025/08/08/3130343/32716/en/Telix-Pharmaceuticals-Limited-TLX-Shares-Fall-Amid-SEC-Subpoena-Hagens-Berman.html
[3] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-telix-pharmaceuticals-limited--tlx-302521589.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet